Trending Stock News

Tekla Capital Management Lifted Sarepta Therapeutics (SRPT) Stake by $1.13 Million; Abbvie (ABBV) Valuation Rose While Finemark National Bank & Trust Has Cut Its Position

Tekla Capital Management Llc increased its stake in Sarepta Therapeutics Inc. (SRPT) by 4.89% based on its latest 2017Q3 regulatory filing with the SEC. Tekla Capital Management Llc bought 25,000 shares as the company’s stock rose 22.49% with the market. The institutional investor held 536,600 shares of the health care company at the end of 2017Q3, valued at $24.34M, up from 511,600 at the end of the previous reported quarter. Tekla Capital Management Llc who had been investing in Sarepta Therapeutics Inc. for a number of months, seems to be bullish on the $3.98B market cap company. The stock increased 4.29% or $2.53 during the last trading session, reaching $61.52. About 2.22M shares traded or 23.78% up from the average. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 96.82% since January 16, 2017 and is uptrending. It has outperformed by 80.12% the S&P500.

Finemark National Bank & Trust decreased its stake in Abbvie Inc (ABBV) by 4.54% based on its latest 2017Q3 regulatory filing with the SEC. Finemark National Bank & Trust sold 5,254 shares as the company’s stock rose 6.17% with the market. The institutional investor held 110,397 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $9.81 million, down from 115,651 at the end of the previous reported quarter. Finemark National Bank & Trust who had been investing in Abbvie Inc for a number of months, seems to be less bullish one the $160.19 billion market cap company. The stock increased 1.08% or $1.07 during the last trading session, reaching $100.34. About 4.37M shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since January 16, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

Investors sentiment increased to 2.88 in Q3 2017. Its up 1.36, from 1.52 in 2017Q2. It is positive, as 24 investors sold SRPT shares while 27 reduced holdings. 63 funds opened positions while 84 raised stakes. 51.70 million shares or 25.22% more from 41.29 million shares in 2017Q2 were reported. Granite Point Cap Management LP accumulated 0.44% or 46,520 shares. Ig Invest Mgmt Ltd invested 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Glenmede Tru Na invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Trexquant LP has invested 0.1% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Morgan Stanley has invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Sigma Planning Corporation invested 0.08% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Tourbillon Cap LP holds 1.68% or 1.53M shares. Metropolitan Life New York holds 0.01% or 39,393 shares. Timessquare Cap Lc, New York-based fund reported 474,450 shares. Qvt Financial Ltd Partnership, a New York-based fund reported 56,949 shares. Neuberger Berman Grp Inc Ltd Liability Corp accumulated 25,000 shares or 0% of the stock. Wells Fargo And Mn holds 300,841 shares. Alliancebernstein Ltd Partnership invested 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). State Board Of Administration Of Florida Retirement Sys holds 29,549 shares or 0% of its portfolio. 43,251 were reported by Citigroup Incorporated.

Among 27 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 21 have Buy rating, 0 Sell and 6 Hold. Therefore 78% are positive. Sarepta Therapeutics had 95 analyst reports since August 5, 2015 according to SRatingsIntel. On Thursday, October 27 the stock rating was initiated by Morgan Stanley with “Equal-Weight”. As per Wednesday, September 6, the company rating was maintained by J.P. Morgan. Wedbush downgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Thursday, April 21 to “Neutral” rating. The firm has “Overweight” rating given on Monday, September 19 by PiperJaffray. The rating was maintained by Jefferies on Wednesday, December 14 with “Hold”. The firm has “Buy” rating by Roth Capital given on Thursday, August 20. As per Tuesday, January 19, the company rating was downgraded by RBC Capital Markets. Piper Jaffray downgraded the stock to “Neutral” rating in Monday, January 18 report. Needham maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Friday, October 2. Needham has “Buy” rating and $55 target. The firm has “Buy” rating by Cowen & Co given on Tuesday, July 18.

Since October 3, 2017, it had 0 insider buys, and 1 sale for $575,000 activity.

Tekla Capital Management Llc, which manages about $1.06B and $2.80B US Long portfolio, decreased its stake in Ovid Therapeutics Inc. by 373,287 shares to 162,537 shares, valued at $1.39 million in 2017Q3, according to the filing. It also reduced its holding in Unitedhealth Group Inc. (NYSE:UNH) by 31,650 shares in the quarter, leaving it with 275,826 shares, and cut its stake in Astrazeneca Plc (NYSE:AZN).

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 11 have Buy rating, 1 Sell and 9 Hold. Therefore 52% are positive. Abbvie Inc had 70 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Buy” rating by Cowen & Co given on Monday, November 20. The firm has “Buy” rating by Jefferies given on Thursday, May 25. The rating was downgraded by JP Morgan to “Neutral” on Thursday, September 8. The rating was upgraded by Citigroup on Tuesday, February 23 to “Buy”. The company was upgraded on Monday, November 2 by Morgan Stanley. Barclays Capital maintained AbbVie Inc. (NYSE:ABBV) rating on Friday, October 13. Barclays Capital has “Equal-Weight” rating and $9 target. Jefferies maintained it with “Buy” rating and $10 target in Friday, September 15 report. Goldman Sachs maintained it with “Buy” rating and $80 target in Friday, March 10 report. The stock of AbbVie Inc. (NYSE:ABBV) earned “Market Perform” rating by Cowen & Co on Monday, June 6. The firm has “Buy” rating given on Tuesday, August 11 by TheStreet.

Finemark National Bank & Trust, which manages about $1.50 billion US Long portfolio, upped its stake in Ishares Tr (EEM) by 9,116 shares to 180,334 shares, valued at $8.08M in 2017Q3, according to the filing. It also increased its holding in Berkshire Hathaway Inc Del (BRKA) by 2 shares in the quarter, for a total of 14 shares, and has risen its stake in Powershares Etf Tr Ii (SPLV).

Since July 31, 2017, it had 0 insider buys, and 8 selling transactions for $45.57 million activity. 87,899 shares were sold by GONZALEZ RICHARD A, worth $6.24M. Shares for $8.57M were sold by RICHMOND TIMOTHY J. on Monday, December 18. On Thursday, December 14 the insider Schumacher Laura J sold $14.07M. $589,512 worth of AbbVie Inc. (NYSE:ABBV) was sold by Michael Robert A.. $705,655 worth of AbbVie Inc. (NYSE:ABBV) was sold by SALEKI-GERHARDT AZITA on Monday, September 11.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *